The paper discusses the distribution of R&D investments for neglected diseases. It does so calculating the Gini index of the investments as related to QALY and and deaths, casued by the various diseases. It turns out that R&D investments are concentrated, not necessarily on the most fatal diseases
Although neglected diseases of developing countries are beginning to receive more attention from com...
According to the World Health Report 2002, preventable or treatable infectious and parasitic disease...
Several studies have assessed whether funding of disease specific research is in line with their bur...
The paper discusses the distribution of R&D investments for neglected diseases. It does so calculati...
The need for new pharmaceutical tools to prevent and treat neglected diseases is widely accepted [1]...
While commonly argued that there is a mismatch between drug innovation and disease burden, there is ...
Background Despite the substantial global burden of disease, rheumatic heart disease research receiv...
This paper analyses the allocation of R&D investments within rare diseases and identifies the charac...
While it is commonly argued that there is a mismatch between drug innovation and disease burden, the...
Introducing patent rights in developing country markets might stimulate greater R and D investment t...
Background: Infectious diseases account for a significant global burden of disease and substantial i...
Abstract: Neglected tropical diseases (NTDs) often afflict the poorest populations of the world. Thi...
AbstractBackgroundInfectious diseases account for a significant global burden of disease and substan...
Our maintained hypothesis is that drug development responds to the intensity of consumer demand. We ...
Background: Economic growth in low- and middle-income countries (LMIC) has raised interest in how di...
Although neglected diseases of developing countries are beginning to receive more attention from com...
According to the World Health Report 2002, preventable or treatable infectious and parasitic disease...
Several studies have assessed whether funding of disease specific research is in line with their bur...
The paper discusses the distribution of R&D investments for neglected diseases. It does so calculati...
The need for new pharmaceutical tools to prevent and treat neglected diseases is widely accepted [1]...
While commonly argued that there is a mismatch between drug innovation and disease burden, there is ...
Background Despite the substantial global burden of disease, rheumatic heart disease research receiv...
This paper analyses the allocation of R&D investments within rare diseases and identifies the charac...
While it is commonly argued that there is a mismatch between drug innovation and disease burden, the...
Introducing patent rights in developing country markets might stimulate greater R and D investment t...
Background: Infectious diseases account for a significant global burden of disease and substantial i...
Abstract: Neglected tropical diseases (NTDs) often afflict the poorest populations of the world. Thi...
AbstractBackgroundInfectious diseases account for a significant global burden of disease and substan...
Our maintained hypothesis is that drug development responds to the intensity of consumer demand. We ...
Background: Economic growth in low- and middle-income countries (LMIC) has raised interest in how di...
Although neglected diseases of developing countries are beginning to receive more attention from com...
According to the World Health Report 2002, preventable or treatable infectious and parasitic disease...
Several studies have assessed whether funding of disease specific research is in line with their bur...
DOI
Add to ORKG